AmplifyBio’s Post

Yesterday, Silo announced that it exercised its option to license SPC-15, a prophylactic treatment for stress-induced affective disorders including anxiety and PTSD, from Columbia University, pursuant to a sponsored research and option agreement established in 2021. Under the terms of the license agreement currently in process, Silo will be granted an exclusive license to further develop, manufacture, and commercialize SPC-15 worldwide. The Company expects to finalize and enter into the exclusive license agreement in the first half of 2024. Dive into the news here: https://bit.ly/3PwTy3g #Biopharma #Research #Biotech #Biopharmaceutical #Science

In case you missed it, Silo recently filed a provisional patent with the USPTO. The patent, titled ‘Methods and Combinations for Managing Pain,’ includes protection for SP-26, our implantable drug delivery system for a novel time-released, dose-controlled formulation of #ketamine, initially targeted for #fibromyalgia. In pre-clinical studies, Silo has reported positive stability of SP-26 for time-release and dosage control. The next tests of the SP-26 ketamine implant will measure drug dissolution and time-release action. More: https://bit.ly/43mM5JG #Science #Biotech #Psychedelics #PsychedelicResearch #Biotechnology

Silo Pharma (Nasdaq: SILO) Files Patent for Groundbreaking #Ketamine Implant Therapeutic to Target #Fibromyalgia and Chronic Pain. Read the press release here: https://bit.ly/43mM5JG #Science #Biotech #Psychedelics #PsychedelicResearch

For all my contacts in the #pharma industry: PwC's ‘IFRS Issues and solutions’ publication for the pharmaceuticals and life sciences industries is our collected insight on the application of IFRS in this industry – reflecting the views of many practitioners in the pharmaceuticals and life sciences industries. The publication has been updated in 2023 and reflects changes in IFRS and interpretations as at that date. http://pwc.to/3v4g0cw #Viewpoint

Indeed, very valuable insights for the accounting issues and solutions, the companies in the life science industry, applying IFRS, should pay attention to in 2024. Worth reading this publication of PWC.

📊 Explore our updated 2023 edition: "IFRS Issues & Solutions for Pharmaceuticals and Life Sciences." Gain expert insights on applying IFRS® Accounting Standards in these industries. Stay informed, promote consistency! #IFRS #Pharma #LifeSciences #PwC

📊 Explore our guide for applying IFRS® Accounting Standards in the Pharmaceuticals and Life Sciences Industry including best practices and real-world examples. #IFRS #Pharma #LifeSciences #PwC

📊 Explore our updated 2023 edition: "IFRS Issues & Solutions for Pharmaceuticals and Life Sciences." Gain expert insights on applying IFRS® Accounting Standards in these industries. Stay informed, promote consistency! #IFRS #Pharma #LifeSciences #PwC

Progress in Medicare drug price negotiations Reuters reports that the Biden administration has advanced in the Medicare program’s inaugural drug price negotiations, responding to offers from manufacturers of 10 high-cost drugs, though specific details of the negotiations remain undisclosed. All companies involved have responded to the initial price offers sent by the Centers for Medicare and Medicaid Services in February, with final prices to be announced on August 1, and the negotiated prices taking effect in 2026. Read more about this and 4 other top stories from the week here: https://bit.ly/43P8uzv Other stories include: - Navigating the future of biopharma collaborations amid U.S.-China tensions - Financial struggles and audit failures threaten Korean biotechs with delisting - Innovative ‘lollipop’ hydrogel for mouth cancer diagnostics developed - White paper proposes solutions to combat drug shortages

🌿💼 Explore Cannabis Financial Metrics: Join Our Free Webinar! 📅 Date: March 18th 🕛 Time: 12pm ET Discover the essential financial insights for success in the Cannabis industry at our upcoming webinar: Cannabis CFO Insights: Metrics To Cultivate Profits. Led by our esteemed virtual Cannabis CFO thought leader, Guillermo Rodriguez, this webinar will cover key topics including cash management, forecasting, profitability levers, and industry benchmarking. Register now for FREE! #CannabisAccounting #Cannabis #CannabisFinance